Instant immunity through chemically programmable vaccination and covalent self-assembly

被引:41
作者
Popkov, Mikhail
Gonzalez, Beatriz
Sinha, Subhash C.
Barbas, Carlos F., III [1 ]
机构
[1] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
基金
美国国家卫生研究院;
关键词
aldolase; angiogenesis; colon cancer; melanoma; tolerance; ALPHA-V INTEGRINS; ADAPTER IMMUNOTHERAPY; ANTIBODY REPERTOIRE; MALIGNANT-MELANOMA; B-CELLS; EXPRESSION; ADHESION; ALPHA(V)BETA(3); MECHANISMS; RECEPTORS;
D O I
10.1073/pnas.0900147106
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The ability to instantly create a state of immunity as achieved in the passive transfer of hyperimmune globulin has had a tremendous impact on public health. Unlike passive immunization, active immunization, which is the foundation of vaccinology, is an anticipatory strategy with inherent limitations. Here we show that elements of active and passive immunization can be combined to create an effective chemistry-driven approach to vaccinology. Reactive immunization was used to create a reservoir of covalent polyclonal antibodies in 3 mouse strains that were subsequently engrafted with syngeneic CT26 colon or B16F10 melanoma tumors. Upon administration of designed integrin alpha(v)beta(3) and alpha(v)beta(5) adapter ligands, the induced covalent polyclonal antibodies self-assembled with the adapter ligands and the animals mounted an instant, chemically programmed, polyclonal response against the implanted tumors. Significant therapeutic responses were observed without recourse to adjuvant therapy. The chemically programmed immune responses were driven by antibody-dependent cellular cytotoxicity and complement-directed cytotoxicity. We suggest that this type of chemistry-driven approach to vaccinology is underexplored and may provide routes to vaccines to protect against diseases that have proven intractable to biology-driven vaccine approaches.
引用
收藏
页码:4378 / 4383
页数:6
相关论文
共 38 条
[1]  
ALBELDA SM, 1990, CANCER RES, V50, P6757
[2]   A RECEPTOR-MEDIATED IMMUNE-RESPONSE USING SYNTHETIC GLYCOCONJUGATES [J].
BERTOZZI, CR ;
BEDNARSKI, MD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1992, 114 (14) :5543-5546
[3]   Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma [J].
Carreiras, F ;
Denoux, Y ;
Staedel, C ;
Lehmann, M ;
Sichel, F ;
Gauduchon, P .
GYNECOLOGIC ONCOLOGY, 1996, 62 (02) :260-267
[4]  
Chattopadhyay N, 2001, J EXP CLIN CANC RES, V20, P269
[5]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[6]   Chemically programmed antibodies:: Endothelin receptor targeting CovX-Bodies™ [J].
Doppalapudi, Venkata R. ;
Tryder, Nancy ;
Li, Lingna ;
Aja, Teresa ;
Griffith, David ;
Liao, Francesca-Fang ;
Roxas, Giovanni ;
Ramprasad, Mysore P. ;
Bradshaw, Curt ;
Barbas, Carlos F., III .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (02) :501-506
[7]   The role of αv integrins during angiogenesis:: insights into potential mechanisms of action and clinical development [J].
Eliceiri, BP ;
Cheresh, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1227-1230
[8]   Mechanisms for decreased function of B cells in aged mice and humans [J].
Frasca, Daniela ;
Landin, Ana Marie ;
Riley, Richard L. ;
Blomberg, Bonnie B. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (05) :2741-2746
[9]   DEFINITION OF 2 ANGIOGENIC PATHWAYS BY DISTINCT ALPHA(V) INTEGRINS [J].
FRIEDLANDER, M ;
BROOKS, PC ;
SHAFFER, RW ;
KINCAID, CM ;
VARNER, JA ;
CHERESH, DA .
SCIENCE, 1995, 270 (5241) :1500-1502
[10]  
Gasparini G, 1998, CLIN CANCER RES, V4, P2625